A review of the current status of siRNA nanomedicines in the treatment of cancer.

DocumentFichier
Fichier pdf chargé le 08/01/2015 à 10:15:18

(version éditeur)
fichier
TitreA review of the current status of siRNA nanomedicines in the treatment of cancer.
Type de publicationArticle de revue
AuteurResnier, Pauline , Montier, Tristan, Mathieu, Véronique, Benoît, Jean-Pierre , Passirani-Malleret, Catherine
EditeurElsevier
TypeArticle scientifique dans une revue à comité de lecture
Année2013
LangueAnglais
Date2013 Sep
Numéro27
Pagination6429-43
Volume34
Titre de la revueBiomaterials
ISSN0142-9612
Mots-clésAnimals, Drug Delivery Systems, Genetic Therapy, Humans, Neoplasms, RNA Interference, RNA, Small Interfering
Résumé en anglais

RNA interference currently offers new opportunities for gene therapy by the specific extinction of targeted gene(s) in cancer diseases. However, the main challenge for nucleic acid delivery still remains its efficacy through intravenous administration. Over the last decade, many delivery systems have been developed and optimized to encapsulate siRNA and to specifically promote their delivery into tumor cells and improve their pharmacokinetics for anti-cancer purposes. This review aims to sum up the potential targets in numerous pathways and the properties of recently optimized siRNA synthetic nanomedicines with their preclinical applications and efficacy. Future perspectives in cancer treatment are discussed including promising concomitant treatment with chemotherapies or other siRNA. The outcomes in human clinical trials are also presented.

URL de la noticehttp://okina.univ-angers.fr/publications/ua6671
DOI10.1016/j.biomaterials.2013.04.060
Lien vers le document

http://dx.doi.org/10.1016/j.biomaterials.2013.04.060

Autre titreBiomaterials
Identifiant (ID) PubMed23727262